Risk factors: Assessment and preventive measures

Clinical Obstetrics and Gynecology

Volumn 41, Issue 4, 1998, Pages 966-975

  Wild, Robert A ^a,b  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; CARDIOVASCULAR RISK; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; GALLBLADDER DISEASE; HORMONE ACTION; HORMONE SUBSTITUTION; HYPERTENSION; HYPERTRIGLYCERIDEMIA; MENOPAUSE; MENTAL DISEASE; OSTEOPOROSIS; REVIEW; RISK FACTOR; VITAMIN SUPPLEMENTATION;

EID: 0032469585     PISSN: 00099201     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003081-199812000-00023     Document Type: Review

References (12)

1. Counseling/health maintenance in precis: an update. Obstet Gynecol. 1998; 23-36.
2. Primary and Preventive Care in Guidelines for Women's Health Care. The American College of Obstetricians and Gynecologists (eds), pp 68, 70, 1995.
3. Utian WH, Shiff I. NAMS-Gallup survey on women's knowledge, information sources, and attitudes to menopause and hormone replacement therapy. Menopause. 1994;1:39-48.
4. NIH Consensus Conference. Optimal calcium intake. NIH Consensus Development Panel on Optimal Calcium Intake. JAMA. 1994;272:1942-1948.
5. Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR. Estrogen replacement therapy and fractures in older women. Study of osteoporotic fractures research group. Ann Intern Med. 1995;122:9-16.
6. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA. 1995;273:199-208.
7. Lobo RA, Pickar JH, Wild RA, Walsh B, Hirvonen E. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. The menopause study group. Obstet Gynecol. 1994;84:987-995.
8. Calle EE, Miracle-McMahill HL, Thun MJ, Health Jr CW. Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. J Natl Cancer Inst. 1995;87:517-523.
9. Grodstein F, Colditz GA, Stampfer MJ. Postmenopausal hormone use and tooth loss: a prospective study. J Am Dent Assoc. 1996;127:372-377.
10. Gebara OC, Mittleman MA, Sutherland P, et al. Association between increased estrogen status and increased fibrinolytic potential in the Framingham offspring study. Circulation. 1995;91:1952-1958.
11. Colditz GA, Hankison SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 1995:332:1589-1593.
12. Newcomb PA, Longnecker MP, Storer BE, et al. Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women. Am J Epidemiol. 1995;142: 788-795.